Abstract：
Despite the approval of new drugs, the inclusion of -omics-derived data and the integration of machine learning in both the diagnostic and therapeutic process, the prognosis of acute myeloid leukemia (AML) remains dismal. The curative path is still aimed at achieving a successful allogeneic hematopoietic stem cell transplant (HSCT) in most patients. Nevertheless, access to this procedure is limited to eligible patients. Moreover, post-HSCT outcomes are influenced by AML heterogeneity and patient-related factors. The rise of venetoclax (VEN)-based combinations as standard of care in the treatment of older or unfit AML patients, together with their peculiar management profile, has led researchers to evaluate the feasibility of this approach in patients proceeding toward HSCT. We reviewed the available evidence to weigh up the advantages and pitfalls of this new therapeutic strategy.
摘要：
尽管新药获得批准,在诊断和治疗过程中包含组学衍生的数据和机器学习的集成，急性髓系白血病(AML)的预后仍然不佳.治疗路径仍旨在在大多数患者中成功实现异基因造血干细胞移植（HSCT）。然而，该程序仅限于符合条件的患者。此外，HSCT后结局受AML异质性和患者相关因素的影响。以维奈托克（VEN）为基础的联合用药作为治疗老年或不适合AML患者的标准治疗，加上他们独特的管理概况，已导致研究人员评估这种方法在接受HSCT的患者中的可行性。我们回顾了现有的证据，以权衡这种新的治疗策略的优点和缺点。
